Jonathan Poole

CIK: 0001604689

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (14.3%)

Derivative conversions

Awards (A)6 (85.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACAD

ACADIA PHARMACEUTICALS INC

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

ACAD
ACADIA PHARMACEUTICALS INC
May 29, 2026
Exercise(M)
Direct
2K shares-
ACAD
ACADIA PHARMACEUTICALS INC
May 29, 2026
Award(A)
Director Stock Options (Right to Buy)
Direct
16K shares-
ACAD
ACADIA PHARMACEUTICALS INC
May 29, 2026
Award(A)
Restricted Stock Units
Direct
9.3K shares-
ACAD
ACADIA PHARMACEUTICALS INC
Mar 3, 2026
Award(A)
Director Stock Options (Right to Buy)
Direct
7.5K shares-
ACAD
ACADIA PHARMACEUTICALS INC
Mar 3, 2026
Award(A)
Director Stock Options (Right to Buy)
Direct
3.6K shares-
ACAD
ACADIA PHARMACEUTICALS INC
Mar 3, 2026
Award(A)
Restricted Stock Units
Direct
4.2K shares-
ACAD
ACADIA PHARMACEUTICALS INC
Mar 3, 2026
Award(A)
Restricted Stock Units
Direct
2K shares-

		Type	Shares	Price		Ownership
May 29, 2026	ACAD ACADIA PHARMACEUTICALS INC	Exercise(M)	2,010	-	$0	Direct
May 29, 2026	ACAD ACADIA PHARMACEUTICALS INC	Award(A) Director Stock Options (Right to Buy)	16,004	-	-	Direct
May 29, 2026	ACAD ACADIA PHARMACEUTICALS INC	Award(A) Restricted Stock Units	9,311	-	-	Direct
Mar 3, 2026	ACAD ACADIA PHARMACEUTICALS INC	Award(A) Director Stock Options (Right to Buy)	7,482	-	-	Direct
Mar 3, 2026	ACAD ACADIA PHARMACEUTICALS INC	Award(A) Director Stock Options (Right to Buy)	3,565	-	-	Direct
Mar 3, 2026	ACAD ACADIA PHARMACEUTICALS INC	Award(A) Restricted Stock Units	4,218	-	-	Direct
Mar 3, 2026	ACAD ACADIA PHARMACEUTICALS INC	Award(A) Restricted Stock Units	2,010	-	-	Direct

1-7 of 7 transactions

About Poole Jonathan

Poole Jonathan (SEC CIK 0001604689) files insider reports with the SEC as Director of ACADIA PHARMACEUTICALS INC (ACAD).

Signal8 holds 3 ownership filings by Poole Jonathan (1 Form 3, 2 Form 4), filed between Mar 20, 2026 and Jun 1, 2026. Those filings report 7 transactions, from Mar 3, 2026 to May 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Poole Jonathan's filings is in SAN DIEGO, CA.

Recent filings by Poole Jonathan

May 29, 2026: Option exercise of ACAD shares (Form 4, code M).
May 29, 2026: Grants or awards of ACAD derivative securities (2 lines, Form 4, code A).
Mar 3, 2026: Grants or awards of ACAD derivative securities (4 lines, Form 4, code A).

Other insiders filing for ACADIA PHARMACEUTICALS INC (ACAD)

Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER
Thompson Elizabeth H.Z., EVP, Head of Research & Dev
Kihara James, PRINCIPAL ACCOUNTING OFFICER
BAKER BROS. ADVISORS LP, Director
HARRIGAN EDMUND, Director
Ndu Adora, Director

How to read Form 4 transaction codes